Home > Tools & Resources > 2022-2023 Interim Flu Vaccine Effectiveness (VE) Results

2022-2023 Interim Flu Vaccine Effectiveness (VE) Results

Reference this summary to review interim VE results for the 2022-2023 influenza season. Early estimates from 2 concurrent studies indicate a substantially reduced risk of medically attended influenza in vaccinated persons aged < 65 years and symptomatic influenza in vaccinated children and adolescents.

Download
Flyer that provides a summary of interim VE estimates from 2 concurrent studies for the 2022-2023 influenza season.

Resource Notes:

Attributes Checklist
  • Provides a QR code to access the full interim results as well as study design and limitations in the Morbidity and Mortality Weekly Report (MMWR)
  • Outlines positive VE outcomes against influenza in children and adults
  • Highlights the importance of influenza vaccination as noted by the CDC

Additional Resources

Flyer with a summary of the ACIP decision to preferentially recommend FLUAD QUADRIVALENT as seasonal influenza vaccine for adults 65+.

FLUAD QUADRIVALENT | CLINICAL

FLUAD® QUADRIVALENT ACIP Recommendation Flyer

Review a summary of the ACIP decision to preferentially recommend FLUAD QUADRIVALENT as seasonal influenza vaccine for adults 65+.

A guide with helpful tips to prepare for and execute a successful flu vaccination campaign.

CLINICAL

Flu Vaccination Campaign Implementation Roadmap

Prepare for and execute a successful annual flu vaccination campaign with these helpful tips.

Flyer with best practices for implementing a flu vaccination and COVID-19 vaccination campaign at the same time.

CLINICAL

Best Practices Flyer - Implementing a Flu Vaccination Campaign During a COVID-19 Vaccination Campaign

Best practices for how to effectively co-administer flu and COVID-19 vaccinations and to use reminders for subsequent administrations.